Catabasis Pharmaceuticals Announces the Initiation of an Open- Label Extension for the MoveDMD ® Trial Studying Edasalonexent (CAT -1004) in Duchenne Muscular Dystrophy

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.